The Medicines Company

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.
Parsippany-Troy Hills, US
Size (employees)
410 (est)-33%
The Medicines Company was founded in 1996 and is headquartered in Parsippany-Troy Hills, US

The Medicines Company Office Locations

The Medicines Company has office in Parsippany-Troy Hills
Parsippany-Troy Hills, US

The Medicines Company Metrics

The Medicines Company Summary

Market capitalization

$3.6 b

Closing share price

The Medicines Company's current market capitalization is $3.6 b.

The Medicines Company Financials

The Medicines Company's revenue is $167.8 m in FY, 2016 which is a 45.7% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$5.1 m$1.3 m$309 m$167.8 m

Revenue growth, %


Net Income

$15.5 m($32.2 m)($352.7 m)($119.2 m)

The Medicines Company Market Value History

The Medicines Company Online Presence

The Medicines Company Company Life

You may also be interested in